Sign in

CIK 0001664710

  • Non-accelerated filer
  • Smaller reporting company

Keros Therapeutics, Inc.

Sign in to watch
Ticker
KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
811173868
Phone
+1 617-314-6297
Business address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$17,830
in 3 filings, $18K under 10b5-1 plans

Net −$17,830. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Prener Anne −$12K Director sold 8% of stake
  2. Newton Charles W. −$6K Director sold 5% of stake
Date Insider Transaction Shares Price Value Owned after
2026-02-24 Regnante Keith CHIEF FINANCIAL OFFICER Grant or award · Employee Stock Option (Right to Buy) +60,000 60,000
2026-02-18 Regnante Keith CHIEF FINANCIAL OFFICER Sale −4,739 $16.35 $77K 39,261
2025-02-18 Regnante Keith CHIEF FINANCIAL OFFICER Grant or award +44,000 44,000
2024-02-13 Regnante Keith CHIEF FINANCIAL OFFICER Grant or award · Employee Stock Option (right to buy) +40,000 40,000
2024-01-04 Regnante Keith CHIEF FINANCIAL OFFICER Exercise or conversion +40,000 $16.00 $640K 40,000
2024-01-04 Regnante Keith CHIEF FINANCIAL OFFICER Sale −40,000 $45.29 $1.8M 0
2024-01-04 Regnante Keith Chief Financial Officer Exercise or conversion · Employee Stock Option (right to buy) −40,000 53,622
2023-11-04 Regnante Keith Chief Financial Officer Exercise or conversion +40,000 $16.00 $640K 40,000
2023-11-04 Regnante Keith Chief Financial Officer Sale −40,000 $45.29 $1.8M 0
2023-06-09 Regnante Keith Chief Financial Officer Exercise or conversion 10b5-1 +20,000 $16.00 $320K 20,000
2023-06-09 Regnante Keith Chief Financial Officer Sale 10b5-1 −15,993 $45.03 $720K 4,007
2023-06-09 Regnante Keith Chief Financial Officer Sale 10b5-1 −1,428 $46.46 $66K 2,579
2023-06-09 Regnante Keith Chief Financial Officer Sale 10b5-1 −2,579 $47.25 $122K 0
2023-06-09 Regnante Keith Chief Financial Officer Exercise or conversion · Employee Stock Option (right to buy) 10b5-1 −20,000 93,622
2023-06-08 Regnante Keith Chief Financial Officer Exercise or conversion 10b5-1 +20,000 $16.00 $320K 20,000
2023-06-08 Regnante Keith Chief Financial Officer Sale 10b5-1 −17,301 $47.66 $825K 2,699
2023-06-08 Regnante Keith Chief Financial Officer Sale 10b5-1 −2,699 $48.65 $131K 0
2023-06-08 Regnante Keith Chief Financial Officer Exercise or conversion · Employee Stock Option (right to buy) 10b5-1 −20,000 113,622
2023-02-16 Regnante Keith Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +40,000 40,000
2022-01-21 Regnante Keith Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +50,000 50,000

Page 1 of 2 · 23 trades